Cytokeratin 20 (KRT20) (Colorectal Epithelial Marker) Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-Cytokeratin 20 (KRT20) (Colorectal Epithelial Marker) antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | Cytokeratin 20 (KRT20) (Colorectal Epithelial Marker) |
| Clone | [KRT20/1992] |
| Host Species | Mouse |
| Reactive Species | human. |
| Isotype | IgG2b, kappa |
| Format | unconjugated |
| Size | 0.02 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (Without BSA & Azide at 1mg/ml) |
| Concentration | n/a |
| Applications | Western Blot (WB), Immunohistochemistry (IHC) Formalin |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | This MAb recognizes an intermediate filament protein of 46kDa, identified as cytokeratin 20 (KRT20). KRT is abundantly expressed in goblet cells and enterocytes of the gastrointestinal tract. It is a useful marker of pancreatic and colorectal cancer. KRT20 is expressed under normal, hyperplastic and neoplastic conditions. It has been detected in adenocarcinomas of the colon, stomach and biliary tract. Breast carcinomas are generally non-reactive. |
| Immunogen | Immunogen: Recombinant human KRT20 protein fragment (around aa 196-323) Cellular Localization: Cytoplasmic |
| Other Names | [CK20; Cytokeratin-20; K20; KA20; Keratin 20; keratin 20, type I; Keratin type I cytoskeletal 20; Keratin-20; KRT20] |
| Gene, Accession # | [KRT20], Gene ID: 54474, NCBI: NP_061883.1, UniProt: P35900 |
| Catalog # | MBS4380474 |
| Price | $190, $340, $340 |
| Order / More Info | Cytokeratin 20 (KRT20) (Colorectal Epithelial Marker) Antibody from MYBIOSOURCE INC. |
| Product Specific References | Moll, R., et al. 1993. The human gene encoding Cytokeratin 20 and its expression during fetal development and in gastrointestinal carcinomas. Differentiation 53: 75-93. Wauters, C.C., et al. 1995. Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. Hum. Pathol. 26: 852-855. |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies